RESUMO
[This corrects the article on p. 21 in vol. 16.].
RESUMO
BACKGROUND: Acalypha wilkesiana (AW, a popular medicinal plant has been used in traditional medicine to treat a variety of skin disorders including pityriasis versicolor and seborrheic dermatitis. As a prelude to clinical trials in humans, an experimental study was carried out to determine the spectrum of antifungal activity of 2 variants of the Acalypha wilkesiana plant. MATERIALS AND METHODS: The ethanol extract and herbal cream formulation of the dried leaves of 2 cultivars (Macrophylla & Hoffmani) of Acalypha wilkesiana were investigated for in-vitro antifungal activity by disc diffusion and micro-broth dilution techniques. Organisms tested were typed cultures of Malassezia furfur, Candida albicans and Trichophyton rubrum; and clinical strains of Microsporum canis and Epidermophyton floccosum. RESULTS: Both cultivars (Macrophylla and Hoffmanii) of the plant showed good activity against all the fungi tested except Microsporum canis (8.0±0.00; 7.00±0.00 mm). The greatest activity was observed against Trichophyton rubrum (22.0±0.00; 24.00±0.00 mm). The Minimum Inhibitory Concentration (MIC) of the crude extract ranged between 0.25 and 8 mg/ml for all organisms, while that of the herbal cream was 0.31-8mg/ml. The lowest MIC was seen with Candida albicans for both varieties of the plant. The Acalypha wilkesiana Hoffmanii demonstrated a greater activity against Candida albicans and Malassezia furufur than the A. wilkesiana Macrophylla. CONCLUSION: This study reveals Acalypha wilkesiana leaf extract has potential for development as a cream that can be used to treat superficial fungal skin infections.
RESUMO
OBJECTIVE: To investigate the antiplasmodial activity of Phyllanthus niruri (P. niruri) methanol extract (ME) and its fractions in mice. METHODS: P. niruri methanol extract and its chloroform, ethanol and aqueous portions were tested against chloroquine-sensitive Plasmodium berghei berghei in early, established and repository models of infection using Knight and Peter's 4-day suppressive model, Ryley and Peters curative model and Peters prophylactic model respectively. RESULTS: Chemosuppression of parasitaemia (37.65%-50.53 %) was elicited by 100-400 mg/kg (b.w.) of ME. At doses of 100 mg/kg b.w., the chloroform fraction (F1) significantly (P<0.01) suppressed parasitaemia by 85.29%, while ethanol and aqueous fractions (F2 and F3, respectively) elicited 67.06% and 51.18% chemosuppression. The most active fraction, F1 was selected for further antiplasmodial screening. In established infection, ME reduced parasitaemia (15.81%-62.96%) while F1 significantly (P<0.01) reduced parasitaemia (44.36%-90.48%), with effects comparable to that of chloroquine (96.48%). The prophylactic antiplasmodial activity of ME (92.50% suppression) was also significant (P<0.01) and was more effective than pyrimethamine (85.00%). Additionally, cell membrane integrity of non-parasitized erythrocytes incubated with 125-500 mg/mL F1 was maintained. CONCLUSIONS: These findings indicate the antiplasmodial efficacy of P. niruri methanol extract, and the localization of this effect in its chloroform fraction.
